A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma (Q80224592)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

title

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Michael G Smylie

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Ralph Wong

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Catalin Mihalcioiu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Chris Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Jean-Francois Pouliot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

7 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

29 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

155-159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16957835%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-006-9002-y

29 December 2019

exact match

0 references

cites work

Phase II study of adriamycin (NSC-123127) in patients with metastatic melanoma

1 reference

12 December 2020

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

12 December 2020

Systemic chemotherapy for the treatment of metastatic melanoma

1 reference

12 December 2020

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy

1 reference

12 December 2020

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience

1 reference

12 December 2020

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment

1 reference

12 December 2020

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

12 December 2020